Emergency treatment of anaphylactic reactions;Akuttherapie anaphylaktischer reaktionen

Allergologie

Volumn 30, Issue 12, 2007, Pages 469-486

  Ring, J ^a,q   Brockow, K ^a   Duda, D ^b   Eschenhagen, T ^c   Fuchs, T ^d   Huttegger, I ^e   Kapp, A ^f   Klimek, L ^g   Muller U ^h   Niggemann, B ⁱ   Pfaar, O ^g   Przybilla, B ^j   Rebien, W ^k   Rietschel, E ^l   Rueff, F ^j   Schnadt, S ^m   Tryba, M ⁿ   Worm, M ⁱ   Sitter, H ^o   Schultze Weminghaus, G ^p  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Katholisches Klinikum Mainz   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e Salzburger Landeskliniken   (Austria)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g Zentrum fur Rhinologie und Allergologie   (Germany)

^h Spital Bern Ziegler   (Switzerland)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^k Klinik für Allgemeine Kinderheilkunde und Jugendmedizin   (Germany)

^l UNIVERSITY OF COLOGNE   (Germany)

^m Deutscher Allergie und Asthmabund   (Germany)

ⁿ KLINIKUM KASSEL   (Germany)

^o PHILIPPS UNIVERSITY MARBURG   (Germany)

^p RUHR UNIVERSITY BOCHUM   (Germany)

^q TECHNICAL UNIVERSITY OF MUNICH   (Germany)

more..

Author keywords

Anaphylaxis; Antihistamines; Emergency treatment catecholamines; Epinephrine; Glucocorticoids

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; AZELASTINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CETIRIZINE; CHLORPHENIRAMINE; DESLORATADINE; DEXTRAN; DIMETINDENE; DIPHENHYDRAMINE; DOPAMINE; EBASTINE; FEXOFENADINE; GLUCOCORTICOID; HETASTARCH; HYDROXYZINE; LEVOCETIRIZINE; LORATADINE; METHYLPREDNISOLONE; MIZOLASTINE; NORADRENALIN; TERFENADINE; VASOPRESSIN;

ANAPHYLAXIS; ASTHMA; BRONCHODILATATION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; HUMAN; HYPOVOLEMIA; PATHOPHYSIOLOGY; PATIENT CARE; REVIEW;

EID: 37649023925     PISSN: 03445062     EISSN: None     Source Type: Journal    
DOI: 10.5414/alp30469     Document Type: Review

References (105)

1. 2-Rezeptorantagonisten. J. Mol. Med. 67, 743-755 (1989).
2. Barnard J.H.: Studies of 400 Hymenoptera sting deaths in the United States. J. Allergy Clin. Immunol. 52, 259-264 (1973).
3. Bellomo R., M. Chapman, S. Finfer, K. Hickling, I. Myburth: Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Autralian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 356, 2139-2143 (2000).
4. Berchtold E., R. Maibach, U. Müller: Reduction of side effects from rush-immunotherapy with honey bee venom by pretreatment with terfenadine. Clin. Exp. Allergy 22, 59-65 (1991).
5. Boldt J.: Volumenersatz beim schwerkranken Intensivpatienten. Anaesthesist 47, 778-785 (1998).
6. Boldt J., H.J. Priebe: Intravascular volume replacement therapy with synthetic colloids: is there an influence on renal function? Anesth. Analg. 96, 376-382 (2003).
7. Bresser H., C.H. Sander, J. Rakoski: Insektenstichnotfâlle in München. Allergo J. 4, 373-376 (1995).
8. Brockow K., D. Vieluf, K. Puschel, J. Grosch, J. Ring: Increased post-mortem serum mast cell tryptase in a fatal anaphylactoid reaction to non-ionic radiocontrast medium. J. Allergy Clin. Immunol. 104, 237-238 (1999).
9. 2-receptor stimulation by circulating epinephrine. N. Engl. J. Med. 309, 1414-1419 (1983).
10. Brown S.G., K.E. Blackman, V. Stenlake, R.J. Heddle: Insect sting anaphylaxis: prospective evaluation of treatment with intravenous adrenaline and volume resuscitation. Emerg. Med. J. 21, 149-154 (2004).
11. Capurro N., R. Levi: The heart as target organ in systemic allergic reactions. Circ. Res. 36, 520-528 (1975).
12. Celik I.: Renal dysfunction after hydroxyethyl starch. In response: Boldt J., H.-J. Priebe Letter to the Editor. Anesth. Analg. 99, 309-310 (2004).
13. Celik I., D. Duda, B. Stinner, K. Kimura, H. Gayek, W. Lorenz: Early and late histamine release induced by albumin, hetastarch and polygeline: some unexpected findings. Inflamm. Res. 52, 408-416 (2003).
14. Celik I., W. Lorenz, B. Stinner, D. Duda, H. Sitter, S. Sauer, A. Junge, M. Hoppe: Clinical modeling randomised trials (CMRTs) in animals as a new intermediate between biological experiments and randomised clinical trials: application to antihistamine prophylaxis in anaesthesia and surgery. Inflamm. Res. 47 (Suppl. 1), S66-S68 (1998).
15. Clark S., S.A. Bock, T.J. Gaeta, B.E. Brenner, R.K. Cydulka, C.A. Camargo: Multicenter study of emergency department visits for food allergies. J. Allergy Clin. Immunol. 113, 347-352 (2004).
16. Clough G.F., P. Boutsiouki, M.K. Church: Comparison of the effects of levocetirizine and loratadine an histamine-induced wheal, flare, and itch in human skin. Allergy 56, 985-988 (2001).
17. Crifo G., A. Bircher: Selbstbehandlung mit Notfallmedikamenten. Allergologie 26, 1516-1523 (2003).
18. Delage C., H.C. Irey: Anaphylactic deaths: a clinicopathologic study of 43 cases. J. Forens. Sci. 17, 525 (1972).
19. Duda D., W. Dick, W. Lorenz: Anaphylactic shock. 4th Congress of the European Resuscitation Council. Resuscitation, Monduzzi, Bologna 1998, 15-19.
20. Eisenberg M.S., T.J. Mengest: Cardiac resuscitation. N. Engl. J. Med. 344, 1304-1313 (2001).
21. Ellis A.K., J.H. Day: Diagnosis and management of anaphylaxis. Can. Med. Assoc. J. 169, 307-311 (2003).
22. Endrich B., J. Ring, M. Intaglietta: Effects of radiopaque contrast media an the microcirculation of the rabbit omentum. Radiology 132, 331-339 (1979).
23. Fisher M.M.D.: Clinical observations on the pathophysiology and treatment of anaphylactic cardiovascular collapse. Anesth. Intens. Care 17, 17-21 (1986).
24. Friedrich J.O., N. Adhikari, M.S. Herridge, J. Beyene: Metaanalysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann. Intern. Med. 142, 510-524 (2005).
25. Genovese A., S. Gross, I. Sakuma, R. Levi: Adenosine promotes histamine H-mediated negative chronotropic and inotropic effects an human atrial myocardium. J. Pharmacol. Exp. Ther. 247, 844-849 (1988).
26. Grant J.A., J.M. Riethuisen, B. Moulaert, C. DeVos: Double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal- and flare response during 24 hours in healthy male subjects. Ann. Allergy Asthma Immunol. 88, 190-197 (2002).
27. Greenberger P.A., R. Patterson: The prevention of immediate generalized reactions to radiocontrast media in high-risk patients. J. Allergy Clin. Immunol. 87, 867-872 (1991).
28. Gronemeyer W.: Noradrenalin statt Adrenalin beim anaphylaktischen Schock. Dtsch. Med. Wochenschr. 102, 101 (1980).
29. Gu X., K.J. Simons, F.E.R. Simons: Administration by sublingual tablet feasible for the first aid treatment of anaphylaxis? A proof-of-concept study. Diophar. Drug Dispos. 23, 213-216 (2002).
30. Hannaway P.J., G.D.K. Hoppler: Severe anaphylaxis and drug induced beta-blockage. N. Engl. J. Med. 308, 1536 (1983).
31. Helbing A., T. Hurni, U.R. Müller, W.J. Pichler: Incidence of anaphylaxis with circulatory symptoms: a study over a 3-year period comprising 940,000 inhabitants of the Swiss Canton Bern. Clin. Exp. Allergy 34, 285-290 (1990).
32. Hepner D.L., M.C. Castells: Anaphylaxis during the perioperative period. Anesth. Analg. 97, 1381-1395 (2003).
33. Hepner M.J., D.R. Ownby, J.A. Anderson, M.S. Rowe, D. Sears-Ewald, E.B. Brown: Risk of systemic reactions in patients taking β-blocker drugs receiving immunotherapy injections. J. Allergy Clin. Immunol. 86, 407-411 (1990).
34. Hermann K., J. Ring: The renin-angiotensin system in patients with repeated anaphylactic reactions during Hymenoptera venom hyposensitization and sting challenge. Int. Arch. Allergy Immunol. 11, 251-256 (1997).
35. Hoffmann B.B.: Catecholamines, sympathomimetic drugs and adrenergic receptor anatagonists. In: Hardman J.G., L.E. Limbird, A. Goodman (eds). Goodman and Gilman: The Pharmaceutical Basis of Therapeutics. McGraw Hill, New York 2002, 215-268.
36. Holgate S.T., G.W. Canonica, F.E. Simons, M. Taglialatela, M. Tharp, H. Timmerman, K. Yanai: Consensus Group on New Generation Antihistamines (CONGA): present Status and recommendations. Clin. Exp. Allergy 33, 1305-1324 (2003).
37. Ickx B.E., F. Bepperling, C. Melot, C. Schulman, P.J. van der Linden: Plasma substitution effects of a new hydroxyethyls starch HES 130/0.4 compared with HES 200/0.5. Br. J. Anaesth. 91, 196-202 (2003).
38. Johansson S.G.O., T. Bieber, R. Dahl, P.S. Friedmann, B.O. Lanier, R.F. Lockey, C. Motala, J.A.O. Martell, T.A.E. Platts-Mills, J. Ring, F. Thien, P.V. Cauwenberge, H.C. Williams: Revised nomenclature for allergy for global use: Report of the nomenclature review committee of the World Allergy Organization. J. Allergy Clin. Immunol. 113, 832-836 (2004).
39. Joint Task Force an Practice Parameters American Academy of Allergy, Asthma and Immunology American College of Allergy, Asthma and Immunology Joint Council of Allergy, Asthma and Immunology: The diagnosis and management of anaphylaxis: an updated practice parameter. J. Allergy Clin. Immunol. 115 (Suppl. 2), 5483-5523 (2005).
40. Kaiser H., H. Kley: Cortisontherapie-Corticoide in Klinik und Praxis. Thieme, Stuttgart 2002.
41. Kasper S.M., P. Meinert, C. Görg, U. Mehlhorn, C. Diefenbach: Large-dose hydroxyethyl starch (HES) 130/0.4 in elective coronary artery bypass surgery. Crit. Care 6, 173 (2002).
42. Kemp S.F., R.F. Lockey: Anaphylaxis: a review of causes and mechanisms. J. Allergy Clin. Immunol. 110, 341-348 (2002).
43. Kill C., E. Wranze, H. Wulf: Successful treatment of severe anaphylactic shock with vasopressin. Two case reports. Int. Arch. Allergy Immunol. 134, 260-261 (2004).
44. Kleine-Tebbe J., T. Fuchs, L. Klimek, J. Kühr, U. Lepp, B. Niggemann, J. Rakoski, H. Renz, J. Saloga, J. Simon: Die spezifische Immuntherapie (Hyposensibilisierung) mit Allergenen. Positionspapier der Deutschen Gesellschaft für Allergologie und klinische Immunologie. Allergo J. 9, 317-324 (2000).
45. Kleinhans D.: Anstrengungsinduzierte Urtikaria und Anaphylaxie. Med. Klin. 82, 103-104 (1987).
46. Laine-Cessac P., H. Moshinaly, J.P. Gouello, P. Geslin, P. Allain: Severe anaphylactoid reaction after intravenous corticosteroids. Report of a case and review of the literature. Therapie 45, 505-508 (1990).
47. Laubenthal H.: Dextrananaphylaxie, Pathomechanismus und Prophylaxe. Ergebnisse einer multizentrischen Studie. Springer, Berlin 1986.
48. Lieberman P.: Use of epinephrine in the treatment of anaphylaxis. Curr. Opin. Allergy Clin. Immunol. 3, 313-318 (2003).
49. 2 antagonists. Ann. Emerg. Med. 36, 462-468 (2000).
50. Lockey R.F., L.M. Benedict, T.B. Turkeltaub, S.C. Bukantz: Fatalities from immunotherapy (IT) and skin testing (ST). J. Allergy Clin. Immunol. 79, 666-677 (1987).
51. Lorenz W., D. Duda, W. Dick, H. Sitter, A. Doenicke, A. Black, D. Weber, H. Menke, B. Stinner, T. Junginger, M. Rothmund, C. Ohmann, M.J.R. Healy: Incidence and clinical importance of perioperative histamine release: randomised study of volume loading and antihistamines after induction of anaesthesia. Lancet 343, 933-940 (1994).
52. Lorenz W., M. Ennis, A. Doenicke, W. Dick: Perioperative uses of histamine antagonists. J. Clin. Anesth. 2, 345-360 (1990).
53. Ludolph-Hauser D., F. Rueff, C. Fries, P. Schöpf, B. Przybilla: Constitutively raised serum concentrations of mast cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet 357, 361-362 (2001).
54. Marone G., M. Bova, A. Detoraki, A.M. Onorati, F.W. Rossi, G. Spadaro: The human heart as a shock organ in anaphylaxis. Novartis Found. Symp. 257, 133-149 (2004).
55. Maulitz R.M., D.S. Pratt, A.L. Schocket: Exercise-induced anaphylactic reaction to shellfish. J. Allergy Clin. Immunol. 63, 433 (1979).
56. Mehl A., U. Wahn, B. Niggemann: Anaphylactic reactions in children - a questionnaire-based survey in Germany. Allergy 60, 1440-1445 (2005).
57. Messmer K.: Plasma substitutes and indications for their use. In: Tinker J., M. Rapin: Care of the critically ill patient. Springer, Berlin 1983, 569-575.
58. Moneret-Vautrin D.A., M. Morisset, J. Flabbee, E. Beaudouin, G. Kanny: Epidemiology of life-threatening and lethal anaphylaxis: a review. Allergy 60, 443-451 (2005).
59. Müller U.: Spätkomplikationen bei Anaphylaxie. In: Ring J., U. Darsow: Allergie 2000: Probleme, Strategien und praktische Konsequenzen. Dustri, München-Deisenhofen 2001, 249-252.
60. Müller U., G. Haeberli: Use of β-blockers during immunotherapy for Hymenoptera venom allergy. J. Allergy Clin. Immunol. 115, 606-610 (2005).
61. Müller U., H. Mosbech, P. Blaauw, S. Dreborg, H.J. Malling, B. Przybilla, R. Urbanek, E. Pastorello, M. Blanca, J. Bousquet, R. Jarisch, L. Youlten: Emergency treatment of allergic reactions to Hymenoptera stings. Clin. Exp. Allergy 21, 281-288 (1991).
62. Nielsen L., C.R. Johnsen, H. Mosbech, L.K. Poulsen, H.J. Malling: Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J. Allergy Clin. Immunol. 97, 1207-1213 (1996).
63. Pavek K., A. Wegmann, L. Nordström, D. Schwander: Cardiovascular and respiratory mechanisms in anaphylactic and anaphylactoid shock reactions. Klin. Wochenschr. 60, 941-947 (1982).
64. Portier P., C. Richet: De l'action anaphylactique de certains venins. C. R. Soc. Biol. 54, 170 (1902).
65. Przybilla B., J. Ring: Anaphylaxis to ethanol and sensitization to acetic acid. Lancet 1, 483 (1983).
66. Przybilla B., F. Rueff, T. Fuchs, C. Pfeiffer, J. Rakoski, W. Stolz, D. Vieluf: Insektengiftallergie. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie. Allergo J. 13, 186-190 (2004).
67. Pumphrey R.S.: Lessons for management of anaphylaxis from a study of fatal reactions. Clin. Exp. Allergy 30, 1144-1150 (2000).
68. Ranft A., E.R. Kochs: Therapie anaphylaktischer Reaktionen: Synopsis bestehender Leitlinien und Empfehlungen. Anästhesiol. Intensivmed. Notfallmed. Schmerzther. 39, 2-9 (2004).
69. Reimers A., U. Müller: Behandlung des anaphylaktischen Schocks. Ther. Umsch. 58, 325-328 (2000).
70. Richet C.: De l'anaphylaxie ou sensibilité croissante des organismes à des doses successives de poison. Arch. Fisiol. 1, 129 (1904).
71. Richter W., H. Hedin, J. Ring, D. Kraft, K. Messmer: Anaphylaktoide Reaktionen nach Dextran I. Immunologische Grundlagen und klinische Befunde. Allergologie 3, 9 (1980).
72. Ring J.: Angewandte Allergologie (3. Aufl.) Urban und Vogel, München 2004.
73. Ring J., H. Behrendt: Anaphylaxis and anaphylactoid reactions. Classification and pathophysiology. Clin. Rev. Allergy Immunol. 17, 387-399 (1999).
74. Ring J., U. Darsow: Idiopathic anaphylaxis. Curr. Allergy Asthma Rep. 2, 40-45 (2002).
75. Ring J., K. Messmer: Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1, 466-469 (1977).
76. 2 receptor antagonists: results of a prospective controlled trial. Int. Arch. Allergy Appl. Immunol. 78, 914 (1985).
77. Rohrer C.L., W.J. Pichler, A. Helbling: Anaphylaxie: Klinik, Ätiologie und Verlauf bei 118 Patienten. Schweiz. Med. Wochenschr. 128, 53-63 (1998).
78. Sampson H.A., A. Munoz-Furlong, S.A. Bock, C. Schmitt, R. Bass, B.A. Chowdhury, W.W. Decker, T.J. Furlong, S.J. Galli, D.B. Golden, R.S. Gruchalla, A.D. Harlor, D.L. Hepner, M. Howarth, A.P. Kaplan, J.H. Levy, L.M. Lewis, P.L. Lieberman, D.D. Metcalfe, R. Murphy, S.M. Pollart, R.S. Pumphrey, L.J. Rosenwasser, F.E. Simons, J.P. Wood, C.A. Camargo: Symposium on the definition and management of anaphylaxis: summary report. J. Allergy Clin. Immunol. 115, 584-591 (2005).
79. Schmittinger C.A., V. Wenzel, K. Herff, K.H. Stadibauer, A.C. Krismer, W.G. Voelckel, H.U. Strohmenger, K.H. Lindner: Medikamentöse Therapie der kardiopulmonalen Reanimation. Anästhesiol. Intensivmed. Notfallmed. Schmerzther. 38, 651-675 (2003).
80. Schwartz L.: Clinical utility of tryptase levels in systemic mastocytoses and associated hematologic disorders. Leuk. Res. 25, 553-562 (2001).
81. Sheikh A., B. Alves: Hospital admissions for acute anaphylaxis: time trend study. BMJ 320, 1441 (2000).
82. 1- antihistamines: clinical relvance. Am. J. Med. 113 (Suppl 9A), 38-46 (2002).
83. 1-antihistamines: more relevant than ever in the treatment of allergic disorders. J. Allergy Clin. Immunol. 112, 42-52 (2003).
84. 1-antihistamines. N. Engl. J. Med. 351, 2203-2217 (2004).
85. Simons F.E.: First-aid treatment of anaphylaxis to food: focus an epinephrine. J. Allergy Clin. Immunol. 113, 837-844 (2004).
86. 1-antihistamines in the skin. J. Allergy Clin. Immunol. 110, 777-783 (2002).
87. Simons F.E.R., X. Gu, L. Jounston, K.J. Simons: Can epinephrine inhalations be substituted for epinephrine injection in children at risk for systemic anaphylaxis? Pediatrics 106, 1040-1044 (2000).
88. Simons F.E.R., X. Gu, K.J. Simons: Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J. Allergy Clin. Immunol. 108, 871-873 (2001).
89. Smedegard G., B. Revenäs, K.E. Arfors: Anaphylaxis in the monkey: hemodynamics and blood flow distribution. Acta Physiol. Scand. 106, 191 (1979).
90. Smith P.L., A. Kagev-Sobotka, E.R. Blecker, R. Traystman, A.P. Kaplan, H. Gralink, M.D. Valentine, S. Permut, L.M. Lichtenstein: Physiologic manifestations of human anaphylaxis. J. Clin. Invest. 60, 1072 (1980).
91. Soto H. de, P. Turk: Cimetidine in anaphylactic shock refractory to standard therapy. Anesth. Analg. 69, 264-265 (1990).
92. Stark B.J., T.J. Sullivan: Biphasic and protracted anaphylaxis. J. Allergy Clin. Immunol. 78, 76-83 (1986).
93. Stoelting R.K.: Systemic circulation. In: Stoelting R.K. (ed.): Pharmacology and Physiology in Anesthetic Practice. Lippincott, Philadelphia 2006, 661-678.
94. Stumpf J.L., N. Shehab, A.C. Patel: Safety of angiotensin- converting enzyme inhibitors in patients with insect venom allergies. Ann. Pharmacother. 40, 699-703 (2006).
95. Sullivan T.J.: Cardiac disorders in penicillin-induced anaphylaxis: association with intravenous epinephrine therapy. JAMA 248, 2161 (1982).
96. Suttner S., J. Boldt: Beeinflusst die Gabe von Hydroxyethylstärke die Nierenfunktion? Anästhesiol. Intensivmed. Notfallmed. Schmerzther. 39, 71-77 (2004).
97. TenBrook J.A., M.P. Wolf, S.N. Hoffmann, L.J. Rosenwasser, M.A. Konstam, D.N. Salem: Should β-blockers be given to patients with heart disease and peanut-induced anaphylaxis? A decision analysis. J. Allergy Clin. Immunol. 113, 977-982 (2004).
98. Toogood H.H.: Risk of anaphylaxis in patients receiving beta-blocker drugs. J. Allergy Clin. Immunol. 81, 1-5 (1988).
99. Tryba M.: Therapie des anaphylaktischen Schocks. Notfallmedizin 23, 238-244 (1997).
100. Tryba M., F.W. Ahnefeld, J. Barth, W. Dick, A. Doenicke, T. Fuchs, H. Gervais, H. Laubenthal, H. Löllgen, W. Lorenz, H.H. Mehrkens, G.H. Meuret, H. Möllmann, S. Piepenbrock, P. Przybilla, J. Ring, W. Schmutzler, G. Schultze-Werninghaus, J. Schüttler, J.P. Schuster, P. Sefrin, J. Zander, M. Zeitz: Akuttherapie anaphylaktoider Reaktionen. Ergebnisse einer interdisziplinären Konsensuskonferenz. Allergo J. 3, 211-224 (1994).
101. Waldhausen E., G. Keser, B. Marquardt: Der anaphylaktische Schock. Anästhesist 36, 150-158 (1987).
102. Walther A., B.W. Bottiger: Anaphylaktoide Reaktionen in der Prähospitalphase. Internist (Berl.) 45, 296-304 (2004).
103. Winbery S.L., P.L. Lieberman: Histamine and antihistamines in anaphylaxis. Clin. Allergy Immunol. 17, 287-317 (2000).
104. Wüthrich B., B.K. Ballmer-Weber: Food-induced anaphylaxis. Allergy 56 (Suppl. 67), 102-104 (2001).
105. Zaloga G.P., W. Delacey, E. Holmboe, S. Chernow: Glucagon reversal of hypotension in a case of anaphylactoid shock. Ann. Intern. Med. 105, 65-66 (1986).